Bushinsky et al. Am J Nephrol 2016;44: (DOI: / )

Slides:

Advertisements

Similar presentations

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Advertisements

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

Discontinuation of medication after nonfatal event: MI

Renalase, a Novel Enzyme Involved in Blood Pressure Regulation, Is Related to Kidney Function but Not to Blood Pressure in Hemodialysis Patients Kidney.

Pleiotropic effects of the non-calcium phosphate binder sevelamer

Am J Nephrol 2013;38: DOI: / Fig. 1. Study selection process.

Volume 57, Issue 5, Pages (May 2000)

Locatelli et al. Am J Nephrol 2017;45: (DOI: / )

Thadhani et al. Am J Nephrol 2017;45:40-48 (DOI: / )

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study Shen et.

PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Fan et al. Am J Nephrol 2017;45: (DOI: / )

Kuwabara et al. Am J Nephrol 2017;45: (DOI: / )

Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:

PCP Perspectives Clinical Considerations in Hyperkalemia

Bhandari et al. Am J Nephrol 2017;45: (DOI: / )

New options for the anemia of chronic kidney disease

Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )

Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology.

A Systematic Review and Meta-Analysis

Simple Cysts in Donor Kidney Contribute to Reduced Allograft Function

Thiazide-Associated Hyponatremia, Report of the Hyponatremia Registry: An Observational Multicenter International Study Burst et al. Am J Nephrol 2017;45:

At The Cutting Edge of Developments in the Management of Hyperkalemia

Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease Torres et al. Am J.

Hammoud et al. Am J Nephrol 2016;44: (DOI: / )

Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients Sprague et al.

Volume 57, Issue 5, Pages (May 2000)

Hyperkalemia in the Hospital

Volume 88, Issue 6, Pages (December 2015)

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

Psychosocial Factors and 30-Day Hospital Readmission among Individuals Receiving Maintenance Dialysis: A Prospective Study Flythe et al. Am J Nephrol 2017;45:

Nutrient Non-equivalence: Does Restricting High-Potassium Plant Foods Help to Prevent Hyperkalemia in Hemodialysis Patients? David E. St-Jules, RD, PhD,

Pregnancy Outcomes in Patients with Glomerular Disease Attending a Single Academic Center in North Carolina O'Shaughnessy et al. Am J Nephrol 2017;45:

Figure 3 Serum phosphate level is associated with

Predictors of disease progression in patients with CKD

Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects Akizawa et.

Pleiotropic effects of the non-calcium phosphate binder sevelamer

Fig. 6-CO, p. 211.

Volume 66, Pages S25-S32 (September 2004)

Nat. Rev. Nephrol. doi: /nrneph

Payan Schober et al. Am J Nephrol 2017;45: (DOI: / )

Charles R. Nolan, Wajeh Y. Qunibi Kidney International

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Nowak et al. Am J Nephrol 2016;44: (DOI: / )

The role of daily dialysis in the control of hyperphosphatemia

Targeting Immunity in End-Stage Renal Disease

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis.

International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes.

Recurrent Vascular Access Dysfunction as a Novel Marker of Cardiovascular Outcome and Mortality in Hemodialysis Patients Kim et al. Am J Nephrol 2016;44:71-80.

Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.

Ionized-to-total magnesium (Mg) and calcium (Ca) ratios are lower in patients on hemodialysis than those in patients not on dialysis. Ionized-to-total.

GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. GLP-1 and gastrin combination therapy increases.

Volume 54, Issue 6, Pages (January 1998)

Genetic Features of Chinese Patients with Gitelman Syndrome:

PTH response to the predialysis serum calcium concentration in hemodialysis patients with severe (A), moderate (B), and mild (C) hyperparathyroidism. PTH.

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Results of aneurysm treatment with flow modification only.

Number of patients treated at clinics that followed up fewer than 10 patients (2013–2016) or 20 patients (2012) and proportion of patients followed up.

Álvares et al. Am J Nephrol 2017;45: (DOI: / )

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

Avasare et al. Am J Nephrol 2017;45:99-106 (DOI: / )

Patient H: changes in circulating sFlt-1 levels and corresponding parameters after two apheresis treatments. Patient H: changes in circulating sFlt-1 levels.

Effect of aspirin (ASA) on serum cytokine concentration in hemodialysis (HD) patients. Effect of aspirin (ASA) on serum cytokine concentration in hemodialysis.

Presentation transcript:

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis Bushinsky et al. Am J Nephrol 2016;44:404-410 (DOI:10.1159/000451067) Table 1. Patient demographic and characteristic information

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis Bushinsky et al. Am J Nephrol 2016;44:404-410 (DOI:10.1159/000451067) Fig. 1. Serum K values over time during the pretreatment week and the patiromer treatment week. HD treatments are indicated by arrows. All patients were admitted to the research unit on a Sunday and started on the controlled diet Monday AM.

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis Bushinsky et al. Am J Nephrol 2016;44:404-410 (DOI:10.1159/000451067) Fig. 2. The proportion of serum K concentrations above the corresponding K value.

Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis Bushinsky et al. Am J Nephrol 2016;44:404-410 (DOI:10.1159/000451067) Fig. 3. Serum Ca and P over time in both the pretreatment week and during the patiromer treatment week. All P binders were stopped on the Sunday of admission. * p = 0.04 compared to the Monday (M) value just prior to the start of the patiromer treatment week.